CSTL: Roth Initiates Buy
Roth Capital initiates coverage on Castle Biosciences with a Buy rating and a price target of $40
Roth Capital analyst Max Masucci initiates coverage on Castle Biosciences (NASDAQ: CSTL ) with a Buy rating and announces Price Target of $40.